The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?

被引：6

作者：

Aoun, Fouad ^{[1
]}

El Rassy, Elie ^{[2
]}

Sleilaty, Ghassan ^{[3
]}

Assi, Tarek ^{[2
]}

Bakouny, Ziad ^{[2
]}

Kattan, Joseph ^{[2
]}

机构：

[1] St Joseph Univ, Hotel Dieu France Univ Hosp, Dept Urol, Fac Med, Beirut, Lebanon

[2] St Joseph Univ, Hotel Dieu France Univ Hosp, Dept Med Oncol, Fac Med, Beirut, Lebanon

[3] St Joseph Univ, Dept Biostat, Fac Med, Beirut, Lebanon

来源：

FUTURE ONCOLOGY | 2017年 / 13卷 / 30期

关键词：

abiraterone acetate; docetaxel; first line; hormone-naive prostate cancer; network meta-analysis; MITOXANTRONE PLUS PREDNISONE; ANDROGEN DEPRIVATION THERAPY; RESISTANCE; ENZALUTAMIDE; METAANALYSIS; AR-V7;

D O I：

10.2217/fon-2017-0445

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To determine whether abiraterone acetate or docetaxel should be regarded as the current standard of care for metastatic hormone-naive prostate cancer (mHNPC). Methods & materials: A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed. Results: The results of this NMA favored abiraterone acetate over docetaxel-based regimens (hazard ratio: 0.79; 95% CI: 0.64-0.99) in patients with mHNPC. The results also suggest a reconsideration of the role of prednisone in view of the absence of a survival benefit (hazard ratio: 0.98; 95% CI: 0.59-1.65) with its use. Conclusion: Despite the paucity of direct comparative evidence, the results of this NMA favor the use of abiraterone acetate in the first-line treatment of mHNPC.

引用

页码：2785 / 2790

页数：6

共 50 条

[1] Treatment of hormone-naive metastatic prostate cancer
Hamilou, Zineb
Saad, Fred
Fizazi, Karim
[J]. CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 334 - 338
[2] Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer
Ramamurthy, Chethan
Handorf, Elizabeth A.
Correa, Andres F.
Beck, J. Robert
Geynisman, Daniel M.
[J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (10) : 688 - 695
[3] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
Feyerabend, S.
Saad, F.
Li, T.
Ito, T.
Diels, J.
Van Sanden, S.
De Porre, P.
Roiz, J.
Abogunrin, S.
Fizazi, K.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[4] Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis
Wallis, Christopher J. D.
Klaassen, Zachary
Bhindi, Bimal
Goldberg, Hanan
Chandrasekar, Thenappan
Farrell, Ann M.
Boorjian, Stephen A.
Kulkarni, Girish S.
Karnes, Robert Jeffrey
Satkunasivam, Raj
[J]. EUROPEAN UROLOGY, 2018, 73 (06) : 834 - 844
[5] Genomic landscape of metastatic hormone-naive prostate cancer
Mizuno, Kei
Akamatsu, Shusuke
Goto, Takayuki
Kobayashi, Takashi
Ogawa, Osamu
[J]. CANCER SCIENCE, 2021, 112 : 656 - 656
[6] In Hormone-Naive Metastatic Prostate Cancer, Should All Patients Now Receive Docetaxel? No, Not Yet
Armstrong, Andrew J.
[J]. ONCOLOGY-NEW YORK, 2014, 28 (10): : 881 - +
[7] Circulating tumor cell in hormone-naive metastatic prostate cancer
Kanayama, M.
Nagaya, N.
Nagata, M.
Horie, S.
[J]. ANNALS OF ONCOLOGY, 2017, 28
[8] Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naive prostate cancer (mHNPC)
Ramamurthy, Chethan
Correa, Andres F.
Handorf, Elizabeth A.
Beck, J. Robert
Geynisman, Daniel M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[9] Medical treatment of patients with hormone-naive metastatic prostate cancer: what's new?
Cathomas, R.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 192 - 192
[10] Metastatic Burden in Hormone-Naive Prostate Cancer: A Tale of Two Subgroups
Haran, A. M.
Ali, A.
Clarke, N. W.
[J]. CLINICAL ONCOLOGY, 2020, 32 (03) : 209 - 212

← 1 2 3 4 5 →